Lab-Grown Psilocybin: Record Yields From Engineered E. coli
Bottom line: Scientists used CRISPR to engineer E. coli bacteria to produce psilocybin and DMT at record-breaking yields.
Scientists have made a groundbreaking achievement by engineering E. coli bacteria to produce psilocybin and DMT using CRISPR, resulting in record-breaking yields of 1.88 g/L and 1.62 g/L, respectively. This innovation has the potential to provide a more stable and scalable supply of psychedelics for medical research, enabling larger-scale studies and exploration of their therapeutic potential.
To understand the significance of this achievement, it’s essential to consider the limitations of traditional plasmid-based expression systems, which can be unstable and variable in gene expression. In contrast, genome-based expression systems, like the one used in this study, involve integrating the genes of interest directly into the bacterial chromosome, providing a more stable and consistent platform for production.
The Genome-vs-Plasmid Problem
Genome-based expression systems offer several advantages over plasmid-based systems, including improved stability and consistency. However, this approach also presents challenges, such as the influence of promoter strength, gene copy number, and chromosomal context on gene expression. The team of researchers addressed these challenges by developing a novel method called ePathIntegrate, which uses CRISPR-associated transposases to integrate and rebalance multigene metabolic pathways in E. coli.
The ePathIntegrate Method
The ePathIntegrate method enables precise control of gene expression and optimization of metabolic pathways, leading to improved productivity and yields. The researchers applied this method to integrate the biosynthetic pathways for psilocybin and DMT into the E. coli genome, resulting in record-breaking production levels. The method involves several key steps, including the design and construction of the genetic pathways, the integration of these pathways into the bacterial genome using CRISPR-associated transposases, and the optimization of gene expression using a library of mutant T7 promoters.
The Numbers
The results of this study are impressive, with the engineered E. coli strains producing psilocybin and DMT at levels of 1.88 g/L and 1.62 g/L, respectively. These yields are significantly higher than those previously reported for plasmid-based systems, which typically range from 100-500 mg/L. The team’s achievement beats the earlier benchmark of 627 mg/L psilocybin production in yeast, demonstrating the potential of the ePathIntegrate method for large-scale production of these complex molecules.
Why It Matters
The successful production of psilocybin and DMT using the ePathIntegrate method has significant implications for medical research. These molecules have shown promise in the treatment of various mental health conditions, including depression, anxiety, and PTSD. However, the current supply of these molecules is limited, and the production process is often cumbersome and expensive. The ePathIntegrate method provides a more stable and scalable platform for the production of these molecules, enabling researchers to conduct larger-scale studies and explore their therapeutic potential more effectively.
This breakthrough complements recent work on engineering plants to produce psychedelic tryptamines, such as the study by Berman et al., which demonstrated the production of five psychedelic tryptamines, including psilocybin, psilocin, DMT, bufotenin, and 5-MeO-DMT, in tobacco plants. For instance, the ePathIntegrate method could be used to produce psilocybin and DMT for clinical trials, which could lead to a better understanding of their therapeutic potential and safety profiles.
The Bigger Picture
The ePathIntegrate method has the potential to improve the production of complex molecules, including psychedelics, and enable the development of new therapies for various diseases. The ability to produce these molecules at large scales and with high consistency will facilitate the conduct of larger-scale clinical trials, which are essential for establishing the safety and efficacy of these molecules as therapeutic agents. The ePathIntegrate method can be applied to the production of other complex molecules, such as antibiotics, vaccines, and enzymes, providing a versatile platform for biotechnology research and development.
Frequently Asked Questions
- What is the ePathIntegrate method, and how does it work? The ePathIntegrate method uses CRISPR-associated transposases to integrate and rebalance multigene metabolic pathways in E. coli, enabling precise control of gene expression and optimization of metabolic pathways.
- What are the potential applications of the ePathIntegrate method? The ePathIntegrate method has the potential to improve the production of complex molecules, including psychedelics, and enable the development of new therapies for various diseases.
- How does the ePathIntegrate method compare to other production methods? The ePathIntegrate method provides a more stable and scalable platform for the production of complex molecules, enabling researchers to conduct larger-scale studies and explore their therapeutic potential more effectively.
- What are the limitations of the ePathIntegrate method? The ePathIntegrate method is still a laboratory-based study, and the results should not be misinterpreted as a product or a treatment. The production of psilocybin and DMT using this method is still a controlled process, and the molecules themselves are regulated substances.
- What further research is needed to establish the potential benefits and risks of psilocybin and DMT as therapeutic agents? Further studies are necessary to establish the safety, efficacy, and dosing of psilocybin and DMT for therapeutic use, as well as to explore their potential applications in various diseases.
Sources
- ¶Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases
- ¶Metabolic engineering of S. cerevisiae for de novo production of psilocybin
- ¶Complete biosynthesis of psychedelic tryptamines in plants
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
